RITZ-5: randomized intravenousTeZosentan (an endothelin-A/B antagonist)for the treatment of pulmonary edema: A prospective, multicenter, double-blind, placebo-controlled study
- 15 January 2003
- journal article
- clinical trial
- Published by Elsevier BV in Journal of the American College of Cardiology
- Vol. 41 (2), 204-210
- https://doi.org/10.1016/s0735-1097(02)02708-0
Abstract
No abstract availableThis publication has 15 references indexed in Scilit:
- Acute heart failure: a novel approach to its pathogenesis and treatmentEuropean Journal of Heart Failure, 2002
- Effects of the dual endothelin-receptor antagonist bosentan in patients with pulmonary hypertension: a randomised placebocontrolled studyThe Lancet, 2001
- Endothelin Mediates the Altered Renal Hemodynamics Associated with Experimental Congestive Heart FailureJournal of Cardiovascular Pharmacology, 2001
- Randomised trial of high-dose isosorbide dinitrate plus low-dose furosemide versus high-dose furosemide plus low-dose isosorbide dinitrate in severe pulmonary oedemaThe Lancet, 1998
- Prognostic impact of big endothelin-1 plasma concentrations compared with invasive hemodynamic evaluation in severe heart failureJournal of the American College of Cardiology, 1996
- Evidence for endothelin-1-mediated vasoconstriction in severe chronic heart failureThe Lancet, 1995
- Endothelin in human congestive heart failure.Circulation, 1994
- Effects of the Early Administration of Enalapril on Mortality in Patients with Acute Myocardial InfarctionThe New England Journal of Medicine, 1992
- Plasma endothelin in chronic heart failure.Circulation, 1992
- A novel potent vasoconstrictor peptide produced by vascular endothelial cellsNature, 1988